Borderless AI Launches Alberni: AI for Global Compliance

TORONTO--(BUSINESS WIRE)--Aug 6, 2026--

Borderless AI, the AI-native global employment platform, today announced the launch of Alberni, the AI-powered legal operating system for global employment law and global entity management. Alberni combines legal expertise with custom AI agents, allowing companies to hire and operate internationally without building a legal department in every country.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806416451/en/

Managing a global team requires not only best-in-class payroll but also best-in-class employment law and compliance. Every new market brings different localized legal and workplace compliance requirements. Until now, companies have managed it all with a patchwork of local law firms, consultants, and spreadsheets, at a cost that scales with every hire and every border crossed.

Alberni was designed to eliminate the need for patchwork solutions. Borderless AI created Alberni as a single platform that pairs legal expertise with in-house AI, enabling companies to maintain a compliant global workforce footprint. This allows companies to handle everything from local entity formation and maintenance to worker classification, statutory deadlines, regulatory change, and workforce disputes. Deep legal expertise sets the foundation; AI makes it fast, consistent, and always on. This means companies no longer have to choose between moving quickly and staying compliant.

The launch comes as AI is rapidly transforming how law firms and in-house legal teams operate. Reports show a clear increase in the use of generative AI by firms and legal departments, with nearly half reporting use of AI in 2026 compared to just one quarter last year. There is a growing wave of new generation AI-native law firms, built without billable hours and staffed by lawyers working alongside AI.

However, legal AI is largely focused on law firms and litigators. Alberni brings the same legal expertise directly to companies. The companies for whom global compliance is a daily operational reality, not a matter for outside counsel. Global employment requires more than legal knowledge. It requires infrastructure, operational experience, and systems that scale. By combining Borderless AI’s global operations know-how with legal expertise, Alberni makes a company's global operations compliant by default in every jurisdiction in which it operates.

“Companies have always faced a barrier to hiring globally while remaining compliant; every new market means more law firms, more retainers, and more risk,” says Willson Cross, CEO and Co-founder of Borderless AI. "We built Alberni so legal and regulatory compliance works like infrastructure: always on, always current, and smarter with every case. The companies that define the next decade will hire everywhere. We’re giving teams an easier and safer way to make that happen.”

With Alberni, companies get:

The launch of Alberni marks an additional step in Borderless AI’s mission to help companies onboard, pay, and manage talent in 170+ countries without hassle.

To learn more about Alberni, visit hireborderless.com/alberni.

About Borderless AI

Borderless AI is an AI-native Employer of Record (EOR) and global payroll platform that helps companies onboard, pay, and manage talent in 170+ countries without setting up foreign entities. Borderless AI combines owned legal entities with real-time global payroll, local benefits, and embedded compliance to enable People and Finance teams to scale globally without sacrificing speed, control, or employee experience. Backed by investors including Aglaé Ventures (LVMH) and Susquehanna International Group, Borderless AI powers hundreds of modern teams across fintech, SaaS, crypto, and consumer brands.

Borderless AI Launches Alberni: AI for Global Compliance

WASHINGTON (AP) — The Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic, manufacturer Moderna said.

The shot, named mFlusiva, is intended for adults age 50 or older. Other brands of flu shots already have begun arriving in pharmacies ahead of fall vaccination season, and Moderna said late Wednesday that it expects some of its new version to be available soon at select retailers.

While there already are multiple flu vaccine options in the U.S., including three specifically recommended for people age 65 or older, tens of thousands of Americans die from influenza every year and older adults are among the most vulnerable.

Flu vaccines must be updated annually to best match circulating strains of the virus. Vaccines made with the Nobel Prize-winning mRNA technology are faster to manufacturer than other types, and experts say this additional option might help if the shape-shifting flu virus mutates in a way that requires suddenly brewing new doses.

Moderna said the FDA granted full approval for mFlusiva’s use in people ages 50 to 64, based on a study of 40,000 people that found 27% fewer flu cases among people who got the new shot compared with those who got a different common flu vaccine brand. For people 65 or older, the Cambridge, Massachusetts-based manufacturer said the FDA granted what’s called accelerated approval for the shot -- based on a smaller study showing it generated a strong immune response compared with an existing high-dose vaccine for seniors – while it conducts an additional study.

Moderna’s data showed no major safety issues although the shot did cause some temporary reactions including injection site pain, fever, headache, tiredness and aches that occurred somewhat more than with today’s flu shots.

The FDA action comes after a highly unusual public dispute over mFlusiva earlier this year. A then-top FDA official blocked the company’s application, a sign of the agency’s heightened vaccine scrutiny under Health Secretary Robert F. Kennedy Jr. Days later, the agency changed course after Moderna publicly challenged the ruling — and in June a panel of independent advisers to the FDA unanimously recommended the vaccine's approval.

Follow the AP's coverage of the U.S. Food and Drug Administration at https://apnews.com/hub/us-food-and-drug-administration.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

FILE - The Food and Drug Administration seal is seen at the Hubert Humphrey Building Auditorium in Washington, April 22, 2025. (AP Photo/Jose Luis Magana, File)